Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.
NCT00248833
Completed
The purpose of this study is to determine if the vaccine called Group B Meningococcal 44/76 MOS NOMV 5D Vaccine is safe and free from side effects and if it will protect people from meningitis. This study will vaccinate three groups of people. In the first 2 groups, the study will be double-blinded. This means that neither the volunteer or the medical team will know which formulation of the vaccine was administered. The third group of volunteers and the medical team will know that they are rece... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
01/29/2018
Locations: Walter Reed Army Institute of Research, Clinical Trials Center, Silver Spring, Maryland
Conditions: Meningitis, Meningococcal, Serogroup B
Register for Updates
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
NCT00766753
Completed
This is a single-institution Phase I/II study designed to evaluate the safety and induction of an immune response, and preliminary clinical response of vaccinations with Type-1 alpha-DCs (alpha-DC1) loaded with glioma-associated antigen (GAA) epitopes and administration of poly-ICLC in patients with recurrent malignant gliomas. Approximately 30 subjects will be enrolled in this study at UPMC/UPCI Hillman Cancer Center. The study participants in this trial will be HLA-A2 positive male or female a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2018
Locations: Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Malignant Glioma
Register for Updates
Cancer Vaccine Targeting Brachyury Protein in Tumors
NCT01519817
Completed
Background: - Cancer vaccines are being developed to help teach the body's immune system to attack and destroy cancer cells. A new vaccine being tested targets Brachyury protein. This protein is present in some tumor cells, and it can help tumor cells spread to other parts of the body. Researchers want to see whether the new Brachyury protein vaccine can help treat people with advanced carcinomas. Objectives: - To test the safety and effectiveness of a cancer vaccine that targets Brachyury pr... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/02/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Neoplasms, Malignant Solid Tumors, Colon Neoplasms, Adenocarcinoma
Register for Updates
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
NCT01685372
Completed
The purpose of this study is to determine whether Fluzone High Dose increases the immune response to the influenza antigens contained in the vaccine compared to standard-dose Fluzone in immunocompromised children and young adults. Safety and efficacy data will also be collected.
Gender:
ALL
Ages:
Between 5 years and 35 years
Trial Updated:
12/21/2017
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT), Dialysis
Register for Updates
Phase 1 Safety and Immunogenicity of Meningococcal Vaccine
NCT00678652
Completed
The purpose of this study is to determine whether a vaccine based on outer membrane vesicles (NOMV) from genetically detoxified group B meningococcus is safe and effective for use as a vaccine. If so, the NOMV in this vaccine will be combined with NOMV from two other genetically modified strains as a potentially globally effective vaccine against group B meningococcus.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
12/15/2017
Locations: Clinical Trials Center, WRAIR, Silver Spring, Maryland
Conditions: Meningococcal Infection, Group B
Register for Updates
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00726739
Completed
RATIONALE: Aldesleukin may stimulate the white blood cells to kill tumor cells. Vaccines may help the body build an effective immune response to kill tumor cells. Giving aldesleukin together with vaccine therapy may kill more tumor cells. It is not yet known whether aldesleukin is more effective with or without vaccine therapy in treating melanoma. PURPOSE: This randomized phase II trial is studying how well aldesleukin works when given with or without vaccine therapy in treating patients with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2017
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Stage IV Melanoma
Register for Updates
Influenza Vaccine Post Allogeneic Transplant
NCT01215981
Terminated
Study Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy adult volunteers will be recruited as controls to confirm immune response to a single influenza vaccine.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
12/03/2017
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Hematopoietic Stem Cell Transplant, Hematologic Malignancy
Register for Updates
Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults
NCT03038243
Withdrawn
This is a research study about an experimental (investigational) oral inactivated whole cell Shigella flexneri 2a killed vaccine (Sf2aWC) and an adjuvant called dmLT. Sf2aWC is a killed vaccine that is being made to prevent disease from Shigella., which causes bloody, watery diarrhea. An adjuvant is something that is added to a vaccine to make it work better. The purpose of the study is to see if the vaccine will protect people from Shigella infection with or without an adjuvant called dmLT. Abo... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
11/16/2017
Locations: Center for Vaccine Development (CVD), University of Maryland School of Medicine, Baltimore, Maryland
Conditions: Shigella Sonnei Dysenteries
Register for Updates
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
NCT02944357
Withdrawn
This pilot clinical trial studies how well gemcitabine hydrochloride, cisplatin, and AGS-003-BLD work in treating patients with bladder cancer that has spread to the muscle and who are undergoing surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from a person's tumor cells may help the body bui... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2017
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
Register for Updates
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
NCT00920218
Completed
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2017
Locations: GSK Investigational Site, Little Rock, Arkansas +10 locations
Conditions: Herpes Zoster
Register for Updates
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART
NCT01378156
Completed
GV-TH-01 is an open label Phase 1 study of 9 HIV-1 infected adults with suppressed viremia who started anti-retroviral therapy (ART) within 18 months of a negative HIV antibody test. This study has 3 phases. The first phase is the vaccination phase, where patients are vaccinated with pGA2/JS7 (JS7)DNA and MVA62B vaccines on a prime/boost regimen. The second phase of the study is a treatment interruption phase, whereby ART is interrupted for a 12 week period approximately 8 weeks following the la... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
11/09/2017
Locations: The University of Alabama at Birmingham Alabama Vaccine Research Clinic, Birmingham, Alabama +2 locations
Conditions: HIV-1 Infection
Register for Updates
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
NCT00622401
Terminated
The purpose of this study is to test the safety of an investigational Dendritic Cell/Tumor Fusion vaccine given with IL-12 for patients with breast cancer. RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Interleukin-12 may stimulate the white blood cells to kill tumor cells. Giving vaccine therapy together with interleukin-12 may kill more tumor cells. PURPOSE: This phase I/II trial is studying... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/12/2017
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates